Skip to main content
COFCO BIOTECHNOLOGY CO., LTD. logo

COFCO BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 000930 ISIN · CNE000000ZR7 LEI · 300300CSR7RNP1P1CP32 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2018-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000930

About COFCO BIOTECHNOLOGY CO., LTD.

https://www.cofcotech.com

COFCO Biotechnology Co., Ltd. specializes in the deep processing of agricultural products, primarily corn, cassava, and other grains. The company operates as a major producer of fuel ethanol, edible alcohol, and starch-based products. Its portfolio includes a wide range of sweeteners such as fructose and glucose, as well as organic acids like citric acid and lactic acid. Additionally, the firm develops bio-based materials and biochemical products including amino acids and feed additives. Serving diverse sectors such as food and beverage, pharmaceuticals, and renewable energy, the company focuses on technological innovation in biotechnology to enhance resource efficiency and promote sustainable industrial applications. It maintains a significant presence in the global supply chain for bio-based chemicals and ingredients.

Recent filings

Filing Released Lang Actions
董事会关于股票连续停牌前股票价格波动未达到中国证券监督管理委员会《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a formal statement from the board of directors of 中粮生物化学(安徽)股份有限公司 regarding the stock price fluctuations before a continuous trading suspension. It references regulatory requirements from the China Securities Regulatory Commission (CSRC) about stock price movements and insider trading investigations. The document provides a detailed explanation and data analysis of stock price changes relative to market and industry indices, concluding that the price changes did not meet the threshold for regulatory concern. The document is not a financial report, earnings release, or audit report, nor is it a notice of voting results or management change. It is a regulatory compliance explanation related to stock price behavior and suspension, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement and explanation without financial statements or report publication. The document length is short (1414 characters), and it is not announcing a report publication but providing a regulatory explanation.
2018-04-23 Chinese
七届七次董事会决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the seventh meeting of the seventh board of directors of 中粮生物化学(安徽)股份有限公司. It discusses the approval of a plan for the issuance of shares to purchase assets, which is a form of major asset restructuring. The document includes voting results, details of the transaction, pricing, lock-up periods, and compliance with relevant laws and regulations. It is not a full financial report but rather a formal board meeting resolution announcement related to a capital transaction and restructuring. This fits the category of Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes through issuance of shares for asset acquisition. The document length and content confirm it is not a brief announcement or a proxy statement, but a substantive board resolution on financing and capital structure changes.
2018-04-23 Chinese
关于披露发行股份购买资产暨关联交易预案暨股票继续停牌的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the disclosure of a plan for issuing shares to purchase assets and related party transactions, along with the continuation of stock suspension. It details the timeline and regulatory approvals required for a major asset restructuring, including multiple references to stock suspension and regulatory filings. The text does not contain actual financial statements or detailed financial data but rather updates on the status of a major asset restructuring and stock suspension. The document length is short (1831 characters) and primarily serves as an announcement of ongoing corporate actions and regulatory compliance. Therefore, it fits best into the category of Capital/Financing Update (CAP), as it relates to a significant financing and capital restructuring event involving share issuance and asset acquisition.
2018-04-23 Chinese
中国国际金融股份有限公司关于公司发行股份购买资产暨关联交易预案之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" regarding the "Issuance of Shares to Purchase Assets and Related Party Transaction Proposal" by COFCO Biochemical (Anhui) Co., Ltd. It contains detailed verification opinions on the transaction proposal, compliance with regulatory requirements, transaction contracts, board resolutions, asset ownership, and risk disclosures. The content focuses on the independent financial advisor's review and opinion on a major asset acquisition transaction involving issuance of shares, which is a typical feature of a Capital/Financing Update or a transaction-related advisory report. It is not a full annual or interim financial report, nor an earnings release or audit report. It is also not a simple announcement or voting result. The document is substantive and detailed, not a brief announcement or certification. Given the nature of the document as an independent financial advisor's verification opinion on a share issuance to purchase assets and related party transaction proposal, the most appropriate classification is Capital/Financing Update (CAP).
2018-04-23 Chinese
七届四次监事会公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of a supervisory board meeting (监事会公告) discussing and approving various resolutions related to a major asset restructuring involving issuance of shares to purchase assets. It includes voting results, legal and regulatory references, transaction details, pricing, lock-up periods, and compliance with relevant laws and regulations. The content focuses on the approval and procedural aspects of a significant capital transaction and asset acquisition, which is characteristic of a Capital/Financing Update. It is not a full annual or interim report, audit report, or earnings release. It is not a simple announcement of a report publication but a substantive disclosure of a financing transaction and related corporate governance matters. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9,340 characters) and detailed content support this classification with high confidence.
2018-04-23 Chinese
独立董事关于发行股份购买资产暨关联交易的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' opinion on a share issuance to purchase assets and related party transaction. It discusses compliance with laws and regulations, board approvals, and fairness of the transaction. It is not a full annual or interim report, nor an earnings release or call transcript. It is a formal opinion related to a capital transaction involving issuance of shares to acquire assets, which is a capital/financing update. The document length is short (2017 characters) and contains substantive content about the transaction, not just an announcement or certification. Therefore, it fits best under Capital/Financing Update (CAP).
2018-04-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.